Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation Therapy for Type 2 Diabetes Mellitus: An Updated Meta-Analysis

Abstract

Introduction Studies of the effects of stem cell therapy on type 2 diabetes mellitus (T2DM) have not reached consistent results. Our meta-analysis aimed to systematically evaluate the efficacy of autologous bone marrow-derived stem cells (ABM-MNCs) on T2DM. Methods We systematically searched PubMed, EMBASE, Web of Science, and the Cochrane Library for studies published between 1980 and May 2018. Two researchers screened the literature independently following the inclusion and exclusion criteria. Meta-analysis of the pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated based on either a fixed- or random-effects model. Results We identified six studies with 206 participants investigating the effects of autologous bone marrow stem cell therapy on T2DM after screening 102 studies found after the initial search. According to the pooled estimates, compared with the control group, after 12-month follow-up the ABM-MNC therapy group had a lower level of HbA1c (MD, − 1.18; 95% CI, − 1.40 to 0.95) and lower required insulin dose (MD, − 2.05; 95% CI, − 3.55 to − 0.55). HbA1c decreased after ABM-MNC therapy compared with before (12 months: MD, − 1.22; 95% CI, − 1.43 to − 1.0). We also observed a significant decrease in insulin requirement after 3-, 6-, 9-, and 12-month follow-up in the ABM-MNC group, respectively. Conclusion Autologous stem cell therapy showed a beneficial effect on T2DM.

Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: A systematic review and meta‐analysis

“…Other studies on the effect of stem cell and bone marrow stem cell transplantation in the treatment of type 2 diabetes have yielded similar results to the current study (reduced HbA1c levels and daily insulin doses, and increased levels of Cpeptide), despite using different sources of stem cells, (bone marrow and peripheral blood) 42,43 .…”

Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease: A Review of the Studies Using Syngeneic, Autologous, Allogeneic, and Xenogeneic Cells

“…In another recent meta-analysis including DM2 individuals ( n = 6 studies, 206 patients), treatment with autologous BM-MNCs (dose ranged from 382.6 ± 10 7 to 2.8 ± 1.9 × 10 9 cells) was effective in reducing HbA1c by 1.18% and insulin requirement during a follow-up of 12 months [ 176 ].…”

Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives

“…In favour of the use of autologous MSCs, a meta-analysis in heart failure patients favoured increased exercise capacity, left ventricular ejection fraction, quality of life and reduced mortality and hospital readmission rates 39 . In another meta-analysis, treatment with whole bone marrow autologous cells (dose ranged from 382.6±10 7 to 2.8±1.9x10 9 ) was effective for reducing glycated haemoglobin (HbA 1c ) by 1.18% and for reducing the need for insulin at 3, 6, 9 and 12 months after treatment 40 .…”